Sensory NeuroStimulation Receives Patent for Restless Legs Syndrome Treatment

The U.S. Patent and Trademark Office has issued a patent for Sensory NeuroStimulation’s Relaxis, the only FDA-cleared device for Restless Legs Syndrome treatment, the San Clemente, Calif., devicemaker announced Thursday.

The device uses a pad to provide vibratory counterstimulation for 30 minutes, gradually decreasing in intensity and turning off while the patient is asleep. The treatment is likened to getting a leg massage.

People afflicted with RLS feel uncomfortable, uncontrollable tingling, aching and dysphoria in their legs. RLS episodes typically occur when a person is at rest, about to sleep or sleeping. Sleep interruptions resulting from RLS can reduce quality of life, cause physical fatigue, limit mental functioning and create emotional stress.

Relaxis is available by prescription only. It won FDA approval last year. — Jason Scott